Immunotherapy for Hodgkin lymphoma
Immunotherapy drugs and treatments are designed to help stimulate the immune system or to help immune cells better identify and attack cancer cells. Checkpoint inhibitor drugs work by blocking signals cancer cells use to hide from the immune system. The U.S. Food and Drug Administration has approved the checkpoint inhibitor drug pembrolizumab (Keytruda®) to treat some patients with classical Hodgkin lymphoma (cHl) whose previous treatment did not work or who have relapsed after receiving three or more types of treatment.
Because immunotherapy treatments may also cause the immune system to attack healthy cells in addition to cancer cells, they may cause side effects, such as flu-like symptoms, fatigue, skin rashes and gastrointestinal problems.